This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kowa Company, Ltd.
Drug Names(s): NK-104, itavastatin, nisvastatin, itabavastin, NKS-104, pitavastatin, Livazo (EU), Alipza (EU), Esteve (EU), Redevant (Mexico)
Description: Like other statins, pitavastatin inhibits HMG CoA Reductase, the first enzyme in the pathway of cholesterol synthesis.
Pitavastatin was discovered in Japan by Nissan Chemical Industries and developed further by Kowa Pharmaceuticals.
Kowa and Daiichi Sankyo
By July 2000, Sankyo had exclusive development and marketing rights for pitavastatin in the US, and shared those rights with Nissan Chemical and Kowa in Japan. In April 2013, Kowa and Daiichi Sankyo announced that the two companies would end their joint marketing partnership for sales of Livalo (Pitavastatin calcium) tablets as of June 30, 2013. The promotion and marketing of Livalo tablets will be conducted solely by Kowa.
Kowa and Solvay
In June 2008, Kowa signed a license agreemnt with Solvay for pitavastatin in the treatment of hypercholesterolemia. The terms of the agreement grant Solvay the exclusive right to commercialize the product in Canada.
Kowa and Recordati
In October 2008, Recordati announced the signature of a new agreement with Kowa Pharmaceutical Europe (KPE), a subsidiary of...See full deal structure in Biomedtracker
Partners: Recordati SpA Esteve, S.A. Merck KGaA Mitsubishi Tanabe Pharma Corporation
Additional information available to subscribers only: